Oral topiramate for treatment of alcohol dependence: A randomised controlled trial

Lancet

Volumn 361, Issue 9370, 2003, Pages 1677-1685

  Johnson, Bankole A ^a   Ait Daoud, Nassima ^a   Bowden, Charles L ^a   DiClemente, Carlo C ^b   Roache, John D ^a   Lawson, Kevin ^a   Javors, Martin A ^a   Ma, Jennie Z ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mail Stop 7792 ^*

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; TOPIRAMATE;

ADULT; AGED; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

EID: 0037649004     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13370-3     Document Type: Article

References (28)

1. Weiss F., Porrino L.J. Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci. 22:2002;3332-3337.
2. Kohl R.R., Katner J.S., Chernet E., McBride W.J. Ethanol and negative feedback regulation of mesolimbic dopamine release in rats. Psychopharmacology. 139:1998;79-85.
3. Dodd P.R., Beckmann A.M., Davidson M.S., Wilce P.A. Glutamate-mediated transmission, alcohol, and alcoholism. Neurochem Int. 37:2000;509-533.
4. Breese C.R., Freedman R., Leonard S.S. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res. 674:1995;82-90.
5. White H.S., Brown S.D., Woodhead J.H., Skeen G.A., Wolf H.H. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 41:(suppl):2000;S17-S20.
6. Moghaddam B., Bolinao M.L. Glutamatergic antagonists attenuate ability of dopamine uptake blockers to increase extracellular levels of dopamine: implications for tonic influence of glutamate on dopamine release. Synapse. 18:1994;337-342.
7. Skradski S., White H.S. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 41:(suppl):2000;S45-S47.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edn. Washington, DC, USA: American Psychiatric Association, 1994.
9. Bohn M.J., Babor T.F., Kranzler H.R. The alcohol use disorders identification test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 56:1995;423-432.
10. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I disorders - patient edition (SCID-I/P, Version 2.0). 1994;New York State Psychiatric Institute, Biometrics Research Department, New York.
11. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured clinical interview for DSM-IV axis I. disorders - patient edition:1994;New York State Psychiatric Institute, Biometrics Research Department, SCID-I/P, Version 2.0)", New York.
12. Miller W.R., Marlatt G.A. Manual for the comprehensive drinker profile. 1984;Psychological Assessment Resources, Odessa, FL.
13. McLellan A.T., Luborsky L., Cacciola J., et al. New data from the addiction severity index: reliability and validity in three centers. J Nerv Ment Dis. 173:1985;412-423.
14. Sobell L.C., Sobell M.B. Timeline follow-back: a technique for assessing self-reported alcohol consumption. Litten R.Z., Allen J.P. Measuring alcohol consumption: psychosocial and biochemical methods. 1992;41-72 Humana Press, Totowa, NJ.
15. Conigrave K.M., Degenhardt L.J., Whitfield J.B., Saunders J.B., Helander A., Tabakoff B. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res. 26:2002;332-339.
16. Moak D.H., Anton R.F., Latham P.K. Further validation of the obsessive-compulsive drinking scale (OCDS): relationship to alcoholism severity. Am J Addict. 7:1998;14-23.
17. Levine J., Schooler N.R. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 22:1986;343-381.
18. Edwards G., Orford J., Egert S., et al. Alcoholism: a controlled trial of "treatment" and "advice" J Stud Alcohol. 38:1977;1004-1031.
19. Fawcett J., Epstein P., Fiester S.J., Elkin I., Autry J.H. Clinical management - imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull. 23:1987;309-324.
20. Bohn M.J., Barton B.A., Barron K.E. Psychometric properties and validity of the obsessive-compulsive drinking scale. Alcohol Clin Exp Res. 20:1996;817-823.
21. Johnson B.A., Roache J.D., Javors M.A., et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA. 284:2000;963-971.
22. Stout R.L., Wirtz P.W., Carbonari J.P., Del Boca F.K. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol. 12:(suppl):1994;70-75.
23. Senn S. Testing for baseline balance in clinical trials. Stat Med. 13:1994;1715-1726.
24. Graybill F.A. Theory and application of the linear model. 1976;Duxbury Press, North Scituate, MA.
25. Hollingshead A.B., Redlich F. Social class and mental illness: a community study. 1958;Wiley, New York.
26. Meinert C.L. Clinical trials: design, conduct, and analysis. 1986;Oxford University Press, New York.
27. Garnett W.R. Clinical pharmacology of topiramate: a review. Epilepsia. 41:(suppl):2000;S61-S65.
28. Johnson B.A., Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology. 149:2000;327-344.